5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
12 citations
,
January 1993 in “PubMed” September 2003 in “Reactions Weekly” 24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
January 2012 in “Курский научно-практический вестник "Человек и его здоровье"” 5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
22 citations
,
March 2003 in “Steroids” PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
April 2017 in “The Journal of urology/The journal of urology” SHH protein helps nerve regeneration in hypertensive rats.
13 citations
,
November 2012 in “PubMed” 5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
April 2017 in “The journal of sexual medicine” 5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
PRP injections with tadalafil and stretching safely improved Peyronie's symptoms but didn't significantly change curvature long-term.
20 citations
,
April 2023 in “The Journal of Urology” PRP is safe but not more effective than a placebo for treating mild to moderate erectile dysfunction.
September 2016 in “Reactions Weekly” Dutasteride and finasteride don't raise erectile dysfunction risk.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
June 2011 in “British Journal of Urology” Regulatory challenges make developing combination therapies in urology difficult and costly.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
34 citations
,
July 1993 in “PubMed”
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
1 citations
,
December 2012 in “I P Pavlov Russian Medical Biological Herald” Finasteride increases P-glycoprotein activity in the liver and kidney.
14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
8 citations
,
January 1991 in “European Urology” Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.
1040 citations
,
October 1992 in “The New England Journal of Medicine” Finasteride effectively treats BPH but may increase sexual dysfunction risk.
October 2025 in “CRC Press eBooks”